Ondine Biomedical Secures First UK NHS Commercial Deal for Antimicrobial Technology
TL;DR
Ondine Biomedical Inc sealed its first commercial deal with an NHS trust, gaining an early advantage in the healthcare market.
The success is attributed to Steriwave's effectiveness in reducing the need for antibiotics, leading to broader NHS adoption and deployment in healthcare facilities.
Ondine Biomedical's Steriwave is making the world a better place by improving healthcare outcomes, reducing antibiotic use, and contributing to antimicrobial resistance efforts.
Ondine Biomedical Inc is expanding its international presence in Canada, UK, and Spain, while also exploring potential in the United States through FDA phase three trials.
Found this article helpful?
Share it with your network and spread the knowledge!
Ondine Biomedical Inc. has achieved a significant commercial milestone with its first National Health Service trust agreement in the United Kingdom. The Canadian antimicrobial photodisinfection specialist's Steriwave technology will be implemented at Pontefract and Pinderfields hospitals following a successful 500-patient elective hip and knee surgical quality initiative conducted at Pontefract. This adoption represents a crucial validation of the technology's effectiveness in clinical settings and demonstrates growing acceptance within the UK healthcare system.
Matt Ross, Vice President of Sales & Marketing at Ondine Biomedical, expressed enthusiasm about this development, noting that it follows demonstrated positive outcomes and favorable health economics. The company now plans to develop a comprehensive business case in collaboration with the York health economics group and Mid Yorkshire to support broader NHS adoption across the United Kingdom. This strategic approach leverages the successful results from the initial implementation to build a compelling case for wider healthcare system integration.
The UK commercial agreement contributes to Ondine's expanding global presence, with Steriwave technology now deployed in eight new healthcare facilities. The technology's footprint spans 22 facilities in Canada while simultaneously expanding its reach in both the UK and Spanish markets. This growth trajectory reflects increasing recognition of the technology's potential to address critical healthcare challenges, particularly in the context of rising antimicrobial resistance concerns worldwide.
Steriwave's effectiveness in reducing antibiotic requirements, as demonstrated in a UK study, positions the technology as a valuable tool in antimicrobial stewardship efforts. The photodisinfection approach aligns with global initiatives to combat antibiotic resistance, offering a non-antibiotic alternative for infection prevention in surgical and other healthcare settings. This alignment with broader public health priorities enhances the technology's relevance and potential impact on healthcare-associated infection rates.
Looking ahead, Ondine Biomedical plans to continue its European market expansion while capitalizing on established success in Canada. The company is also exploring potential United States market entry through Food and Drug Administration phase three clinical trials. These strategic initiatives reflect Ondine's commitment to establishing Steriwave as a globally recognized solution for healthcare-associated infection prevention. The company's innovative photodisinfection technology represents a promising approach in the ongoing battle against antibiotic resistance, offering healthcare providers an additional tool to improve patient outcomes and reduce reliance on traditional antibiotics.
Curated from News Direct
